<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Immunol</journal-id><journal-title>BMC Immunology</journal-title><issn pub-type="epub">1471-2172</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2172-10-14</article-id><article-id pub-id-type="pmid">19298652</article-id><article-id pub-id-type="doi">10.1186/1471-2172-10-14</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Interferon-gamma coordinates CCL3-mediated neutrophil recruitment <italic>in vivo</italic></article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Bonville</surname><given-names>Cynthia A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>bonvillc@upstate.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Percopo</surname><given-names>Caroline M</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>percopoc@niaid.nih.gov</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Dyer</surname><given-names>Kimberly D</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>kdyer@niaid.nih.gov</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Gao</surname><given-names>Jiliang</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jgao@niaid.nih.gov</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Prussin</surname><given-names>Calman</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>cprussin@niaid.nih.gov</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Foster</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><email>bfoster@cablespeed.com</email></contrib><contrib id="A7" corresp="yes" contrib-type="author"><name><surname>Rosenberg</surname><given-names>Helene F</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>hrosenberg@niaid.nih.gov</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Domachowske</surname><given-names>Joseph B</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>domachoj@upstate.edu</email></contrib></contrib-group><aff id="I1"><label>1</label>SUNY Upstate Medical University, Syracuse, New York 13210, USA</aff><aff id="I2"><label>2</label>Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA</aff><aff id="I3"><label>3</label>Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA</aff><aff id="I4"><label>4</label>Proteus Technologies, 133 National Business Parkway, Suite 150, Annapolis Junction, Maryland, 20701, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>19</day><month>3</month><year>2009</year></pub-date><volume>10</volume><fpage>14</fpage><lpage>14</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2172/10/14"/><history><date date-type="received"><day>12</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>19</day><month>3</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Bonville et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Bonville et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Bonville A Cynthia bonvillc@upstate.edu </dc:author><dc:title> Interferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivo </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Immunology 10(1): 14-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2172(2009)10:1&#x0003c;14&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2172</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>We have shown previously that acute infection with the respiratory pathogen, pneumonia virus of mice (PVM), results in local production of the proinflammatory chemokine, CCL3, and that neutrophil recruitment in response to PVM infection is reduced dramatically in CCL3 -/- mice.</p></sec><sec><title>Results</title><p>In this work, we demonstrate that CCL3-mediated neutrophil recruitment is coordinated by interferon-gamma (IFN&#x003b3;). Neutrophil recruitment in response to PVM infection was diminished five-fold in IFN&#x003b3; receptor gene-deleted mice, although neutrophils from IFN&#x003b3;R -/- mice expressed transcripts for the CCL3 receptor, CCR1 and responded functionally to CCL3 <italic>ex vivo</italic>. Similarly, in the absence of PVM infection, CCL3 overexpression alone could not elicit neutrophil recruitment in the absence of IFN&#x003b3;. Interestingly, although supplemental IFN&#x003b3; restored neutrophil recruitment and resulted in a sustained weight loss among CCL3-overexpressing IFN&#x003b3; -/- mice, CCL3-mediated neutrophil recruitment alone did not result in the pulmonary edema or respiratory failure characteristic of severe viral infection, suggesting that CCL3 and IFN-&#x003b3; together are sufficient to promote neutrophil recruitment but not pathologic activation.</p></sec><sec><title>Conclusion</title><p>Our findings reveal a heretofore unrecognized hierarchical interaction between the IFN&#x003b3; and CCL3, which demonstrate that IFN&#x003b3; is crucial for CCL3-mediated neutrophil recruitment <italic>in vivo</italic>.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Most respiratory virus infections are relatively benign and self-limited events. However, infection with highly pathogenic viruses can result in more severe sequelae, in which disease progresses to respiratory failure due to uncontrolled inflammation, pulmonary edema, and damage to lung tissue [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B5">5</xref>].</p><p>As part of an ongoing effort to understand inflammatory responses during severe respiratory virus infection, we have developed an inhalation model using the natural rodent pathogen, pneumonia virus of mice (PVM). Originally identified by Horsfall and colleagues [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>], PVM is a pneumovirus (family <italic>Paramyxoviridae</italic>) that is closely related to respiratory syncytial virus (RSV), and is among the few characterized mouse models of virus-induced acute respiratory distress syndrome (ARDS) [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]. Among the prominent features of this infection, a minimal intranasal inoculum (30 &#x02013; 100 pfu) results in robust virus replication within bronchial epithelial cells that is accompanied by profound granulocyte recruitment. In the absence of pharmacologic intervention, PVM infection progresses to pulmonary edema and respiratory compromise, similar to the more severe forms of RSV infection experienced by human infants [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. In our earlier studies, we identified the chemokine CCL3 (MIP-1&#x003b1;) as a crucial component of this inflammatory response. PVM not only elicits production of CCL3 by infected bronchial epithelial cells [<xref ref-type="bibr" rid="B12">12</xref>], mice devoid of CCL3 or its receptor, CCR1, recruit dramatically fewer neutrophils to airways [<xref ref-type="bibr" rid="B13">13</xref>]. Blockade of the CCL3/CCR1 proinflammatory signaling pathway in conjunction with antiviral therapy resulted in improved survival in response to an otherwise lethal virus inoculum [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. As CCL3 is only one of several major pro-inflammatory signaling pathways activated by PVM infection [<xref ref-type="bibr" rid="B12">12</xref>], there is certainly the possibility of additive, synergistic, or hierarchical means to promote and to amplify the ongoing inflammatory response.</p><p>Although first identified as a component of the antiviral response to Sindbis virus [<xref ref-type="bibr" rid="B16">16</xref>], the role of the Th1 cytokine, interferon-&#x003b3; (IFN&#x003b3;) in pneumovirus infection remains uncertain. IFN&#x003b3; is readily detected in bronchoalveolar lavage fluid and nasal washings from RSV-infected infants [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>], and minimal or absent response has been correlated with poor clinical outcome [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B24">24</xref>]. IFN&#x003b3; is also detected in BAL fluid of BALB/c mice in response to challenge with RSV virions [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>] and plays a role in limiting the inflammatory response to secondary challenge and in generating the allergic histopathology in response to formalin-fixed RSV vaccine antigens and virion components [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>]. Likewise, local production of IFN&#x003b3; is a prominent response to PVM infection [<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>], although its role in modulating the primary inflammatory response has not yet been fully explored.</p><p>In this manuscript, we explore the role of IFN&#x003b3; in modulating the inflammatory response to PVM infection, and utilize overexpression analysis to begin a dissection of the independent and interdependent contributions of both IFN-&#x003b3; and CCL3 to the process of neutrophil recruitment <italic>in vivo</italic>.</p></sec><sec><title>Results</title><sec><title>Microarray profiling of IFN&#x003b3; expression in response to PVM infection</title><p>Transcript encoding the cytokine IFN&#x003b3; was detected in mouse lung tissue at various time points in response to PVM infection [<xref ref-type="bibr" rid="B12">12</xref>]. In response to a non-lethal inoculum of PVM strain J3666, IFN&#x003b3; mRNA was detected above baseline levels beginning on day 5. IFN-&#x003b3; mRNA levels peak at day 7 after inoculation, and fall rapidly to baseline between days 7 &#x02013; 14. Shown in Figure <xref ref-type="fig" rid="F1">1A</xref> are profiles of the 203 transcripts (of total 45,101 transcripts on the 430_2 mouse chip) that display kinetic expression correlations of 0.900 or greater with the IFN-&#x003b3; profile, as per the 'find similar' algorithm of Genespring GX 7.3. Selected transcripts, categorized by function, are listed in Table <xref ref-type="table" rid="T1">1</xref>. Among the transcripts that correlate with the IFN&#x003b3; profile are 17 characterized interferon-response genes. Most intriguing is the close correlation (0.965) between the expression patterns of IFN&#x003b3; and CCL3 (MIP-1&#x003b1;). CCL3 is essential for granulocyte recruitment in response to PVM infection [<xref ref-type="bibr" rid="B13">13</xref>]. As shown in Figure <xref ref-type="fig" rid="F1">1B</xref>, there is a significant correlation between levels of immunoreactive IFN&#x003b3; and CCL3 in lung tissue from individual PVM-infected mice.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>(A) Expression of transcripts in mouse lung tissue in response to PVM infection: IFN-&#x003b3; and IFN-&#x003b3; correlating profiles</bold>. Baseline expression in uninfected mice (day 0) is set at 1.0 and normalized expression (per gene, per chip) is shown for days 1 &#x02013; 7, 10, 14, 21 and 28 after inoculation. Profiles of 203 transcripts with patterns that correlate with that the profile of IFN-&#x003b3; (0.900 to 0.969) are shown in yellow to red, respectively, and identified by name in Table 1. The expression profile of CCL3 (MIP-1&#x003b1;), a chemokine crucial for neutrophil recruitment in response to PVM infection, is overdrawn with a blue line (correlation 0.965). <bold>(B) Correlation of IFN-&#x003b3; and CCL3 protein levels in individual PVM-infected mice</bold>. IFN-&#x003b3; and CCL3 detected by ELISA in lung tissue homogenates from individual mice days 0 &#x02013; 28 after inoculation with 30 pfu PVM (n = 43) are as shown. <bold>(C) IFN&#x003b3;<sup>+ </sup>NK and T cells detected in lungs of PVM-infected mice</bold>. Total and IFN&#x003b3;<sup>+ </sup>NK cells, CD4<sup>+ </sup>T cells, and CD8<sup>+ </sup>T cells (&#x000b1; sd) detected per lung on day 6 after inoculation with 10 pfu PVM.</p></caption><graphic xlink:href="1471-2172-10-14-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Expression profiles that correlate with IFN-&#x003b3; in PVM-infected mouse lung tissue.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Transcript</bold></td><td align="left"><bold>Symbol</bold></td><td align="left"><bold>Acc. No.</bold></td><td align="left"><bold>Correl.</bold></td></tr></thead><tbody><tr><td align="left"><bold>Interferon-&#x003b3; and related transcripts</bold></td><td></td><td></td><td></td></tr><tr><td align="left">Interferon-&#x003b3;</td><td align="left">Ifng</td><td align="left"><ext-link ext-link-type="gen" xlink:href="K00083">K00083</ext-link></td><td align="left">1.000</td></tr><tr><td align="left">Interferon inducible protein 1</td><td align="left">Ifi1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_008326">NM_008326</ext-link></td><td align="left">0.961</td></tr><tr><td align="left">Interferon-stimulated protein</td><td align="left">Isg20</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BC022751">BC022751</ext-link></td><td align="left">0.953</td></tr><tr><td align="left">Interferon-&#x003b3; induced GTPase</td><td align="left">Igtp</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_018738">NM_018738</ext-link></td><td align="left">0.953</td></tr><tr><td align="left">Interferon-induced transmembrane protein 6</td><td align="left">Ifitm6</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BB193024">BB193024</ext-link></td><td align="left">0.950</td></tr><tr><td align="left">CXC chemokine ligand 11 (IP-9)</td><td align="left">Cxcl11</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_019494">NM_019494</ext-link></td><td align="left">0.949</td></tr><tr><td align="left">Interferon inducible protein 47</td><td align="left">Ifi47</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_008330">NM_008330</ext-link></td><td align="left">0.940</td></tr><tr><td align="left">Interferon activatible protein 203</td><td align="left">Ifi203</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AI607873">AI607873</ext-link></td><td align="left">0.932</td></tr><tr><td align="left">Interferon activated gene 205</td><td align="left">Ifi205</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AI481797">AI481797</ext-link></td><td align="left">0.929</td></tr><tr><td align="left">Interferon induced protein with tetratricopeptide repeats 1</td><td align="left">Ifit1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_008331">NM_008331</ext-link></td><td align="left">0.929</td></tr><tr><td align="left">Interferon consensus sequence binding protein 1</td><td align="left">Icsbp1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BG069095">BG069095</ext-link></td><td align="left">0.926</td></tr><tr><td align="left">Interferon regulatory factor 7</td><td align="left">Irf7</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_016850">NM_016850</ext-link></td><td align="left">0.922</td></tr><tr><td align="left">Interferon activated gene 205</td><td align="left">Ifi205</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AI481797">AI481797</ext-link></td><td align="left">0.916</td></tr><tr><td align="left">Interferon regulatory factor 5</td><td align="left">Irf5</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_012057">NM_012057</ext-link></td><td align="left">0.914</td></tr><tr><td align="left">Interferon activated gene 203</td><td align="left">Ifi203</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_008328">NM_008328</ext-link></td><td align="left">0.910</td></tr><tr><td align="left">Interferon-induced protein with tetratricopeptide repeats, 3</td><td align="left">Ifit3</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_010501">NM_010501</ext-link></td><td align="left">0.909</td></tr><tr><td align="left">Interferon induced protein with tetratricopeptide repeats 2</td><td align="left">Ifit2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_008332">NM_008332</ext-link></td><td align="left">0.901</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold>Other inflammation-associated transcripts</bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">CC Chemokine ligand 3 (MIP-1&#x003b1;)</td><td align="left">Ccl3</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_011337">NM_011337</ext-link></td><td align="left">0.965</td></tr><tr><td align="left">Toll-like receptor 2</td><td align="left">Tlr2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_011905">NM_011905</ext-link></td><td align="left">0.959</td></tr><tr><td align="left">Interleukin-13 receptor alpha 1</td><td align="left">Il13ra1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="S80963">S80963</ext-link></td><td align="left">0.959</td></tr><tr><td align="left">Suppressor of cytokine signaling 3</td><td align="left">Socs3</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_007707">NM_007707</ext-link></td><td align="left">0.951</td></tr><tr><td align="left">Galectin-9</td><td align="left">Lgals9</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_010708">NM_010708</ext-link></td><td align="left">0.948</td></tr><tr><td align="left">Interleukin-1 receptor antagonist</td><td align="left">Il1rn</td><td align="left"><ext-link ext-link-type="gen" xlink:href="M57525">M57525</ext-link></td><td align="left">0.947</td></tr><tr><td align="left">Regulator of G-protein signaling 19 interacting protein 1</td><td align="left">Rgs19ip1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_018771">NM_018771</ext-link></td><td align="left">0.943</td></tr><tr><td align="left">Interleukin-6</td><td align="left">Il6</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_031168">NM_031168</ext-link></td><td align="left">0.937</td></tr><tr><td align="left">CD244 natural killer cell receptor 2B4</td><td align="left">Cd244</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_018729">NM_018729</ext-link></td><td align="left">0.928</td></tr><tr><td align="left">CSF2 receptor</td><td align="left">Csf2rb2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_007781">NM_007781</ext-link></td><td align="left">0.928</td></tr><tr><td align="left">Fc receptor, IgG, high affinity, I</td><td align="left">Fcgr1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AF143181">AF143181</ext-link></td><td align="left">0.926</td></tr><tr><td align="left">CC chemokine receptor 1</td><td align="left">Ccr1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AV231648">AV231648</ext-link></td><td align="left">0.926</td></tr><tr><td align="left">Pentaxin-related gene</td><td align="left">Ptx3</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_008987">NM_008987</ext-link></td><td align="left">0.926</td></tr><tr><td align="left">CXC chemokine ligand 13 (BLC)</td><td align="left">Cxcl13</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AF030636">AF030636</ext-link></td><td align="left">0.921</td></tr><tr><td align="left">CXC chemokine ligand 2 (MIP-2&#x003b1;)</td><td align="left">Cxcl2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_009140">NM_009140</ext-link></td><td align="left">0.919</td></tr><tr><td align="left">CXC chemokine ligand 5 (ENA-78)</td><td align="left">Cxcl1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BB554288">BB554288</ext-link></td><td align="left">0.914</td></tr><tr><td align="left">Arginase II</td><td align="left">Arg2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_009705">NM_009705</ext-link></td><td align="left">0.904</td></tr><tr><td align="left">Signal transducer and activator of transcription 1</td><td align="left">Stat1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AW214029">AW214029</ext-link></td><td align="left">0.904</td></tr><tr><td align="left">Regulator of G-protein signaling 1</td><td align="left">Rgs1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_015811">NM_015811</ext-link></td><td align="left">0.903</td></tr><tr><td align="left">CC chemokine receptor-like 2</td><td align="left">Ccrl2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AJ318863">AJ318863</ext-link></td><td align="left">0.902</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold>Various</bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Membrane-spanning 4-domains, subfamily A, member 8A</td><td align="left">Ms4a8a</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_022430">NM_022430</ext-link></td><td align="left">0.969</td></tr><tr><td align="left">Chondroitin sulfate proteoglycan 2</td><td align="left">Cspg2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BM251152">BM251152</ext-link></td><td align="left">0.963</td></tr><tr><td align="left">Fas death domain-associated protein</td><td align="left">Daxx</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_007829">NM_007829</ext-link></td><td align="left">0.960</td></tr><tr><td align="left">O-acyltransferase domain containing 1</td><td align="left">Oact1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AV366860">AV366860</ext-link></td><td align="left">0.960</td></tr><tr><td align="left">Mitogen activated protein kinase kinase kinase kinase 1</td><td align="left">Map4k1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BB546619">BB546619</ext-link></td><td align="left">0.960</td></tr><tr><td align="left">Lymphocyte cytosolic protein 2</td><td align="left">Lcp2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BC006948">BC006948</ext-link></td><td align="left">0.959</td></tr><tr><td align="left">Solute carrier family 15, member 3</td><td align="left">Slc15a3</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_023044">NM_023044</ext-link></td><td align="left">0.956</td></tr><tr><td align="left">Indoleamine-pyrrole 2,3 dioxygenase</td><td align="left">Indo</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_008324">NM_008324</ext-link></td><td align="left">0.954</td></tr><tr><td align="left">Proteosome subunit beta type 9</td><td align="left">Tap1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AW048052">AW048052</ext-link></td><td align="left">0.952</td></tr><tr><td align="left">Phospholipase A1 member A</td><td align="left">Pla1a</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_134102">NM_134102</ext-link></td><td align="left">0.949</td></tr><tr><td align="left">Methylene tetrahydrofolate dehydrogenase</td><td align="left">Mthfd2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BG076333">BG076333</ext-link></td><td align="left">0.949</td></tr><tr><td align="left">Pre-B colony enhancing factor 1</td><td align="left">Pbef1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AW989410">AW989410</ext-link></td><td align="left">0.948</td></tr><tr><td align="left">Thioredoxin reductase 1</td><td align="left">Txnrd1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BB284199">BB284199</ext-link></td><td align="left">0.948</td></tr><tr><td align="left">CGG triplet repeat binding protein 1</td><td align="left">Cggbp1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BI080272">BI080272</ext-link></td><td align="left">0.945</td></tr><tr><td align="left">Sphingosine kinase 1</td><td align="left">Sphk1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AF068749">AF068749</ext-link></td><td align="left">0.944</td></tr><tr><td align="left">Pyrophosphatase</td><td align="left">Pyp</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_026438">NM_026438</ext-link></td><td align="left">0.944</td></tr><tr><td align="left">2'-5' oligoadenylate synthetase 1G</td><td align="left">Oas1g</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BC018470">BC018470</ext-link></td><td align="left">0.943</td></tr><tr><td align="left">Ubiquitin D</td><td align="left">Ubd</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_023137">NM_023137</ext-link></td><td align="left">0.943</td></tr><tr><td align="left">Apolipoprotein D</td><td align="left">Apod</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_007470">NM_007470</ext-link></td><td align="left">0.940</td></tr><tr><td align="left">Membrane-spanning 4-domains, subfamily A, member 4C</td><td align="left">Ms4a4b</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_029499">NM_029499</ext-link></td><td align="left">0.936</td></tr><tr><td align="left">AT rich interacting domain 5A</td><td align="left">Arid5a</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BC027152">BC027152</ext-link></td><td align="left">0.935</td></tr><tr><td align="left">Hemopoietic cell kinase</td><td align="left">Hck</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_010407">NM_010407</ext-link></td><td align="left">0.933</td></tr><tr><td align="left">Histocompatibility 2, complement component factor B</td><td align="left">H2-Bf</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_008198">NM_008198</ext-link></td><td align="left">0.933</td></tr><tr><td align="left">ATP binding cassette</td><td align="left">Abcc5</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BB436535">BB436535</ext-link></td><td align="left">0.933</td></tr><tr><td align="left">Cholesterol 25-hydroxylase</td><td align="left">Ch25h</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_009890">NM_009890</ext-link></td><td align="left">0.932</td></tr><tr><td align="left">BING 4 protein</td><td align="left">Bing4</td><td align="left"><ext-link ext-link-type="gen" xlink:href="C78559">C78559</ext-link></td><td align="left">0.932</td></tr><tr><td align="left">Thymidylate kinase, LPS inducible</td><td align="left">Tyki</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AK004595">AK004595</ext-link></td><td align="left">0.930</td></tr><tr><td align="left">Tripartite motif protein 30</td><td align="left">Trim30</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BM240719">BM240719</ext-link></td><td align="left">0.929</td></tr><tr><td align="left">Tissue specific transplantation antigen 30</td><td align="left">Tsta3</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_031201">NM_031201</ext-link></td><td align="left">0.929</td></tr><tr><td align="left">Syndecan binding protein</td><td align="left">Sdcbp</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AV227603">AV227603</ext-link></td><td align="left">0.928</td></tr><tr><td align="left">Prostaglandin-endoperoxide synthase 2</td><td align="left">Ptgs2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="M94967">M94967</ext-link></td><td align="left">0.926</td></tr><tr><td align="left">Traf binding protein</td><td align="left">T2bp</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BB277065">BB277065</ext-link></td><td align="left">0.925</td></tr><tr><td align="left">Two pore segment channel 2</td><td align="left">Tpcn2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BC025890">BC025890</ext-link></td><td align="left">0.925</td></tr><tr><td align="left">Early growth response 2</td><td align="left">Egr2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="X06746">X06746</ext-link></td><td align="left">0.925</td></tr><tr><td align="left">GLI pathogenesis-related 2</td><td align="left">Glipr2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BM208214">BM208214</ext-link></td><td align="left">0.925</td></tr><tr><td align="left">Cytochrome p450, family 7, subfamily b</td><td align="left">Cyp7b1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_007825">NM_007825</ext-link></td><td align="left">0.924</td></tr><tr><td align="left">Rab20, Ras oncogene</td><td align="left">Rab20</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BG066967">BG066967</ext-link></td><td align="left">0.923</td></tr><tr><td align="left">Solute carrier 39</td><td align="left">Slc39a14</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BB399837">BB399837</ext-link></td><td align="left">0.922</td></tr><tr><td align="left">Dual specificity phosphatase 3</td><td align="left">Dusp3</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BQ266434">BQ266434</ext-link></td><td align="left">0.922</td></tr><tr><td align="left">Ribosome binding protein 1</td><td align="left">Rrbp1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AF273691">AF273691</ext-link></td><td align="left">0.922</td></tr><tr><td align="left">Spermidine synthase</td><td align="left">Srm</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_009272">NM_009272</ext-link></td><td align="left">0.921</td></tr><tr><td align="left">Ubiquitin-specific protease 18</td><td align="left">Usp18</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_011909">NM_011909</ext-link></td><td align="left">0.920</td></tr><tr><td align="left">Lipocalin</td><td align="left">Lcn2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="X14607">X14607</ext-link></td><td align="left">0.920</td></tr><tr><td align="left">Jun-B oncogene</td><td align="left">Junb</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_008416">NM_008416</ext-link></td><td align="left">0.919</td></tr><tr><td align="left">Guanylate nucleotide binding protein 3</td><td align="left">Gbp3</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_018734">NM_018734</ext-link></td><td align="left">0.919</td></tr><tr><td align="left">Pre-B cell colony-enhancing factor 1</td><td align="left">Pbef1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AW989410">AW989410</ext-link></td><td align="left">0.917</td></tr><tr><td align="left">Membrane-spanning 4-domains subfamily A, member 6B</td><td align="left">Ms4a6b</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_027209">NM_027209</ext-link></td><td align="left">0.917</td></tr><tr><td align="left">SLAM family member 7</td><td align="left">Slamf7</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AK016183">AK016183</ext-link></td><td align="left">0.915</td></tr><tr><td align="left">Ras and Rab interactor 1</td><td align="left">Rin1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BC011277">BC011277</ext-link></td><td align="left">0.915</td></tr><tr><td align="left">Class II transactivator</td><td align="left">C2ta</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AF042158">AF042158</ext-link></td><td align="left">0.913</td></tr><tr><td align="left">Myxovirus resistance I</td><td align="left">Mx1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="M21039">M21039</ext-link></td><td align="left">0.910</td></tr><tr><td align="left">Chloride channel calcium activated 2</td><td align="left">Clca1</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AF108501">AF108501</ext-link></td><td align="left">0.910</td></tr><tr><td align="left">Rap2C, member of RAS oncogene family</td><td align="left">Rap2c</td><td align="left"><ext-link ext-link-type="gen" xlink:href="AK008416">AK008416</ext-link></td><td align="left">0.910</td></tr><tr><td align="left">Tumor necrosis factor, alpha induced protein 2</td><td align="left">Tnfaip2</td><td align="left"><ext-link ext-link-type="gen" xlink:href="NM_009396">NM_009396</ext-link></td><td align="left">0.908</td></tr><tr><td align="left">SLAM family member 8</td><td align="left">Slamf8</td><td align="left"><ext-link ext-link-type="gen" xlink:href="BC024587">BC024587</ext-link></td><td align="left">0.908</td></tr></tbody></table><table-wrap-foot><p>The microarray analysis software package, Genespring GX 7.3 'find similar' function was used to inspect all transcript profiles for patterns related to that displayed by IFN-&#x003b3;. The minimum correlation considered to be similar was set at 0.900 (see Figure 1A).</p></table-wrap-foot></table-wrap></sec><sec><title>Detection IFN&#x003b3;<sup>+ </sup>NK and T cells in PVM infected lung tissue</title><p>Both total and IFN&#x003b3;<sup>+ </sup>subsets of NK cells, CD4<sup>+ </sup>and CD8<sup>+ </sup>T cells were enumerated in single cell suspensions of lung tissue from PVM-infected BALB/c mice evaluated at day 6 after inoculation with 10 pfu PVM strain J3666 [Figure <xref ref-type="fig" rid="F1">1C</xref>]. Only a small fraction (&#x0003c;2%) of the CD4<sup>+ </sup>T cells detected at this time point stained positively for IFN&#x003b3;, in contrast to the larger fraction of IFN&#x003b3;<sup>+</sup>CD8<sup>+ </sup>T cells detected (9.9 &#x000b1; 0.6 &#x000d7; 10<sup>3 </sup>cells, 11% of total CD8<sup>+ </sup>T cells). Interestingly, 23% of the total NK cells (3.4 &#x000b1; 0.9 &#x000d7; 10<sup>3 </sup>cells) stained positively for IFN&#x003b3;, an increase from 0.3 &#x000b1; 0.08 &#x000d7; 10<sup>3 </sup>cells, or 4% of the total NK cells detected in a single lung from uninfected mice (data not shown).</p></sec><sec><title>IFN&#x003b3;-dependent responses to PVM infection</title><p>Wild type and IFN&#x003b3; receptor gene deleted (IFN&#x003b3;R -/-) mice were infected with PVM and various parameters relating to the inflammatory response were assessed. Neutrophil recruitment to the airways was markedly diminished in IFN&#x003b3;R -/- mice [Figure <xref ref-type="fig" rid="F2">2A</xref>], reduced from 54 &#x000b1; 11 per 10 hpfs among wild type to 10 &#x000b1; 1.3 hpfs among IFN&#x003b3;R -/- mice, as determined on cytospin preparations of cells in BAL fluid (p &#x0003c; 0.001). These findings are consistent with those of Frey and colleagues [<xref ref-type="bibr" rid="B30">30</xref>], who described reduced inflammation in association with reduced IFN&#x003b3; production in the lungs of PVM infected, T-cell deficient mice. Given our earlier studies on the essential role of CCL3 in eliciting neutrophil recruitment, it is interesting to note that the absence of IFN&#x003b3; signaling had no impact on local production of this chemokine in response to PVM infection [Figure <xref ref-type="fig" rid="F2">2B</xref>]. IFN&#x003b3; was also detected in response to PVM infection in both wild type and in IFN&#x003b3;R-/- mice, albeit at higher levels among the latter group, most likely due to the absence of feedback inhibition (data not shown). The diminished neutrophil recruitment, while significant, was not as profound as that observed in mice subjected to complete blockade of CCL3-mediated signaling, in which we observed 10<sup>4</sup>-10<sup>5 </sup>fold-diminished neutrophil recruitment [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. As might be anticipated from the diminished inflammatory response, we observe a statistically significant increase in virus titer among the IFN&#x003b3;R-/- mice [Figure <xref ref-type="fig" rid="F2">2C</xref>], although this difference is likewise not as dramatic as that observed in response to complete blockade of CCL3 signaling.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Neutrophil recruitment in response to PVM infection is diminished in IFN-&#x003b3;R gene-deleted mice</bold>. <bold>(A) </bold>Neutrophils detected in BAL fluid 5 days after inoculation; hpf, high power field; *p &#x0003c; 0.001;<bold>(B) </bold>Detection of CCL3 in BAL fluid; *p &#x0003c; 0.001 <bold>(C) </bold>Virus copy number detected in lung tissue determined by quantitative RT-PCR.</p></caption><graphic xlink:href="1471-2172-10-14-2"/></fig></sec><sec><title>Receptor expression and responses of neutrophils from IFN&#x003b3;R gene-deleted mice</title><p>As part of an initial attempt to determine whether neutrophils from IFN&#x003b3;R -/- mice were capable of responding to CCL3, we explored receptor expression and ligand-mediated calcium flux in neutrophils isolated from both gene-deleted and wild type mice. As shown in Figure <xref ref-type="fig" rid="F3">3A</xref>, both wild type and IFN&#x003b3;R-/- neutrophils express transcripts encoding CCR1, the major receptor for CCL3; no significant difference in absolute copy number was determined. Likewise, CCL3 induced dose-dependent intracellular calcium flux in both gene-deleted and wild type neutrophils [Figure <xref ref-type="fig" rid="F3">3B</xref>], demonstrating that neutrophils from IFN&#x003b3;R-/- mice have the innate capacity to respond to this chemoattractant ligand; the EC50s and maximum calcium fluxes detected were indistinguishable between the wild type and gene-deleted strains.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Comparison of wild type and IFN&#x003b3;R gene-deleted neutrophils</bold>. <bold>(A) </bold>Expression of CCR1 transcript in wild type and IFN&#x003b3;R gene-deleted neutrophils (n = 9 and 6 independent samples, respectively) determined by quantitative RT-PCR; horizontal line denotes mean copy number. <bold>(B) </bold>Calcium flux (RFU) measured in response to increasing concentrations (0 &#x02013; 500 nM) of CCL3.</p></caption><graphic xlink:href="1471-2172-10-14-3"/></fig></sec><sec><title>Overexpression of CCL3</title><p>In order to examine the independent and interdependent contributions of CCL3 and IFN&#x003b3; to the process of neutrophil recruitment <italic>in vivo</italic>, we generated a method for overexpression of CCL3 <italic>in vivo</italic>. CCL3 was detected in lung tissue homogenates [Figure <xref ref-type="fig" rid="F4">4A</xref>], reaching levels similar to those detected in lung tissue of mice in response to PVM infection [<xref ref-type="bibr" rid="B12">12</xref>]. Immunoreactive CCL3 was detected in bronchial epithelial cells [Figure <xref ref-type="fig" rid="F4">4B</xref>]. No CCL3-positive cells were detected in lung tissue from mice challenged with control vector (vctrl) [Figure <xref ref-type="fig" rid="F4">4C</xref>].</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Heterologous expression of CCL3 in mouse lungs</bold>. <bold>(A) </bold>Detection of immunoreactive CCL3 in lungs of mice on day 9 after challenge via intranasal inoculation with the CCL3 overexpression vector (vCCL3) or control vector (vctrl), *p &#x0003c; 0.01. <bold>(B) </bold>Lung tissue from mice challenged with vCCL3, immunohistochemical localization of CCL3 within bronchiolar epithelial cells (at arrows), <bold>(C) </bold>Lung tissue from mice challenged with vctrl.</p></caption><graphic xlink:href="1471-2172-10-14-4"/></fig></sec><sec><title>Inflammatory responses to IFN&#x003b3; and CCL3</title><p>We examined neutrophil recruitment in response to CCL3 overexpression in IFN&#x003b3; gene-deleted mice (IFN&#x003b3; -/-) with and without IFN&#x003b3; supplementation. As shown in Figure <xref ref-type="fig" rid="F5">5A</xref>, few neutrophils are detected in BAL fluid at baseline (vctrl) and no recruitment over baseline is observed in response to IFN&#x003b3; alone. Likewise, overexpression of CCL3 in the absence of IFN&#x003b3; does not elicit neutrophil recruitment. Neutrophil recruitment (~10 &#x02013; fold over baseline) was observed in response to CCL3 expression only in the presence of IFN&#x003b3;. At the microscopic level, no inflammation was observed in lung tissue of IFN&#x003b3; -/- mice in response to CCL3 overexpression alone [Figure <xref ref-type="fig" rid="F5">5B</xref>]. In contrast, significant pathology was observed in lung tissue of IFN&#x003b3; -/- mice expressing CCL3 and supplemented with exogenous IFN&#x003b3;. Findings include moderate peribronchiolar granulocytic infiltration and substantial parenchymal involvement but minimal edema fluid within the bronchioles and in the parenchymal tissue [Figure <xref ref-type="fig" rid="F5">5C</xref>]. Interestingly, weight loss is sustained among the mice overexpressing CCL3 while receiving supplemental IFN&#x003b3; over the 9 day examination period [Figure <xref ref-type="fig" rid="F5">5D</xref>], but, despite the substantial inflammatory response, we observe no progression to respiratory failure up to and including t = 14 days.</p><fig position="float" id="F5"><label>Figure 5</label><caption><p><bold>Neutrophil recruitment in response to CCL3 is ablated in IFN-&#x003b3; gene-deleted mice</bold>. <bold>(A) </bold>Neutrophils detected in BAL fluid of IFN&#x003b3; gene-deleted (IFN&#x003b3; -/-) mice (+vctrl +med (medium; RPMI + 10% FCS vehicle control); open bar), + IFN&#x003b3; (+vctrl + IFN&#x003b3;, grey-shaded bar), +vCCL3 +med (black bar), or +vCCL3 + IFN&#x003b3; (black-shaded bar); *p &#x0003c; 0.01 vs. other conditions, day 9 after challenge with vCCL3 or vctrl. <bold>(B, C) </bold>Microscopic images of lung tissue from IFN-&#x003b3; -/- mice challenged with <bold>(B) </bold>vCCL3 + med or <bold>(C) </bold>vCCL3 + IFN&#x003b3;; original magnification, 20&#x000d7;. Inset, original magnification 63&#x000d7;, documenting neutrophil recruitment. <bold>(D) </bold>Change in body weight in response to CCL3 overexpression &#x000b1; IFN-&#x003b3;; *p &#x0003c; 0.01 at time points shown.</p></caption><graphic xlink:href="1471-2172-10-14-5"/></fig></sec></sec><sec><title>Discussion</title><p>In previous work, we demonstrated that the actions of the chemokine, CCL3, signaling via its receptor CCR1, were crucial for granulocyte recruitment to the lungs in response to PVM infection [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]; CCL3 has also been shown to be a crucial mediator of granulocyte recruitment in mouse models of influenza [<xref ref-type="bibr" rid="B31">31</xref>]. Paradoxically, CCL3 gene-deletion results in augmented neutrophil and eosinophil recruitment in response to <italic>Cryptococcus neoformans </italic>infection [<xref ref-type="bibr" rid="B32">32</xref>]. Here we show that CCL3-mediated neutrophil recruitment depends directly on IFN&#x003b3; signaling, both in the setting of acute virus infection and in response to heterologous CCL3 expression in the respiratory epithelium.</p><p>Granulocyte recruitment is a primary finding in severe respiratory virus infection; activation of granulocytes can result in the release of proinflammatory cytokines and proteolytic enzymes that can contribute to the ongoing lung damage [<xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B37">37</xref>]. Interestingly, although neutrophils are recruited to the lung parenchyma in response to CCL3 via coordination by IFN&#x003b3;, these cytokines alone clearly are not sufficient to induce the inflammatory state that ultimately promotes lung damage and respiratory failure. Thus, despite our findings demonstrating improved survival from PVM infection with CCR1 blockade [<xref ref-type="bibr" rid="B15">15</xref>], and those of He and colleagues [<xref ref-type="bibr" rid="B38">38</xref>], who likewise demonstrated that CCR1 antagonism provided protection against neutrophil-mediated lung injury in a mouse model of acute pancreatitis, the results presented here, in which we observe neutrophil recruitment but minimal clinical disease, suggest that neutrophil recruitment and neutrophil activation are to some extent distinct and discrete signaling events. It will be crucial to identify the proinflammatory mediators that activate and well as those that recruit neutrophils in order to have a complete picture of the proinflammatory state characteristic of PVM infection.</p><p>The experimental studies performed in this manuscript utilize both IFN&#x003b3; and IFN&#x003b3;R gene-deleted mice, which are in BALB/c and C57BL/6 background strains, respectively. PVM infection has been explored systematically in several inbred strains of mice by Anh and colleagues [<xref ref-type="bibr" rid="B39">39</xref>] who determined that the C57BL/6 strain is somewhat more resistant to infection than BALB/c, but that both of these inbred strains can ultimately succumb to the sequelae of severe disease. We have used both of these strains extensively for our studies (reviewed in [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B9">9</xref>]) and both respond to PVM infection with robust virus replication in lung tissue, granulocyte recruitment and local production of proinflammatory cytokines, including CCL3 and IFN&#x003b3;; no systematic differences, other than the aforementioned susceptibility to infection, have been detected.</p><p>Both CCL3 and IFN&#x003b3; have been detected in human studies and in mouse models of other severe respiratory virus infections, including avian influenza, SARS coronavirus, and human respiratory syncytial virus [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B40">40</xref>-<xref ref-type="bibr" rid="B47">47</xref>], although the potential for interplay between these specific signaling pathways has not been considered previously. Our data suggest that that IFN&#x003b3; and CCL3 signaling pathways, both crucial features of the response to pneumovirus infection, interact in a hierarchical fashion, as IFN&#x003b3; does not elicit neutrophil recruitment on its own [Figure <xref ref-type="fig" rid="F5">5A</xref>], but is crucial for CCL3 to function effectively. Interactions between IFN&#x003b3; and CCL3 may occur at the level of signal transduction, or via alterations to the neutrophil itself. As has been documented clearly, CCL3 can function alone to induce changes in calcium concentration and chemotactic responses in mouse neutrophils <italic>in vitro </italic>[<xref ref-type="bibr" rid="B48">48</xref>]. The current literature on interactions of IFN&#x003b3; with granulocytes was recently reviewed [<xref ref-type="bibr" rid="B49">49</xref>]. Among the possibilities that may address our findings, Hansen and Finbloom [<xref ref-type="bibr" rid="B50">50</xref>] reported that human neutrophils express IFN&#x003b3; receptors and Bonecchi and colleagues [<xref ref-type="bibr" rid="B51">51</xref>] have shown that human neutrophils respond to IFN&#x003b3; with increased expression of a variety of mediators and receptors, including the primary CCL3 receptor, CCR1. It is unclear whether mouse neutrophils respond in a similar fashion, and whether or not these defined molecular responses take place <italic>in vivo</italic>, although we have shown here that neutrophils from IFN&#x003b3;R gene-deleted mice express transcripts for CCR1 and mobilize intracellular calcium in response to CCL3 when examined <italic>ex vivo</italic>. We have not yet explored the possibility that the IFN&#x003b3; coordinates neutrophil recruitment in response to CCL3 in a more indirect fashion, possibly via one or more intermediary cytokines. An example of this phenomenon was reported by Khader and colleagues [<xref ref-type="bibr" rid="B52">52</xref>], who demonstrated that <italic>Mycobacterium tuberculosis</italic>-infected dendritic cells from IL-12p40 gene-deleted mice that were unresponsive to a CCL19 gradient were also overproducing the cytokine IL-10. Most intriguing, addition of IL-10 to wild-type dendritic cells reproduced the inhibited chemotaxis response.</p></sec><sec><title>Conclusion</title><p>In summary, we demonstrate here that CCL3, a proinflammatory mediator produced in response to RSV and shown to be a crucial in recruiting neutrophils in response to the mouse pneumovirus, PVM, functions via a hierarchical relationship with IFN&#x003b3;. Specifically, CCL3 recruits neutrophils to the lung <italic>in vivo </italic>only in coordination with IFN&#x003b3;-mediated signaling pathways. The mechanism via which IFN&#x003b3; modulates neutrophil responses to CCL3 is an intriguing subject for future exploration.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Microarray analysis</title><p>Generation of gene microrarray data was as described previously [<xref ref-type="bibr" rid="B12">12</xref>]. Data collected were evaluated using the microarray software analysis package Genespring GX 7.3. The 'find similar' function was used to inspect all 45,101 transcript profiles in order to detect kinetic profiles similar to that of IFN&#x003b3;. The minimum correlation to be considered a similar profile was set at 0.900. The higher the correlation coefficient (maximum 1.000 for complete overlap), the more similar the gene expression profiles.</p></sec><sec><title>Mouse, virus and vector stocks</title><p>BALB/c and C57BL/6 mice were purchased from Taconic Laboratories (Germantown, NY and Rockville, MD). Homozygous IFN&#x003b3; gene-deleted (IFN&#x003b3; -/-) mice [<xref ref-type="bibr" rid="B53">53</xref>] on a BALB/c background and IFN&#x003b3; receptor gene-deleted (IFN&#x003b3;R -/-) mice [<xref ref-type="bibr" rid="B54">54</xref>] on a C57BL/6 background were purchased from Jackson Laboratories, Bar Harbor, ME. All animal studies were performed as per approved protocols CHUA #634 (SUNY Upstate) or LAD 8E (NIAID). PVM strain J3666 was passaged, stored and quantitated as described previously [<xref ref-type="bibr" rid="B13">13</xref>]. Mice were anaesthetized and inoculated by intranasal challenge with 30 &#x02013; 100 plaque forming units (pfu) PVM also as previously described. For challenge with recombinant vectors (described as follows), dilutions of secondary stock aliquots of vCCL3 and vctrl (described in the section to follow) were prepared in RPMI cell culture medium. Under brief anaesthesia, mice were inoculated with 150 &#x003bc;l of stock (50 &#x003bc;l/dose &#x000d7; 3 doses) to achieve challenges of 1.0 &#x02013; 1.5 &#x000d7; 10<sup>11 </sup>pfu per mouse. On days indicated, mice in each challenge group were sacrificed by cervical dislocation and bronchoalveolar lavage (BAL) fluid, total lung protein and total lung RNA were harvested. For some experiments, mice received 15 &#x003bc;g recombinant murine IFN&#x003b3; (R&#x00026;D Systems, Minneapolis, MN) diluted in tissue culture medium (RPMI + 10% fetal calf serum) or tissue culture medium (vehicle) via intraperitoneal injection one day prior to intranasal challenge with the vCCL3 or vctrl which yielded 323 &#x000b1; 28 pg IFN&#x003b3;/mg lung on day 4 post-inoculation.</p></sec><sec><title>Flow cytometric determination of IFN&#x003b3;<sup>+ </sup>NK and T cells in mouse lung tissue</title><p>Whole lungs of BALB/c mice (uninfected or day 6 after inoculation with 10 pfu PVM, n = 5 per datapoint) were cut into ~3 mm<sup>3 </sup>pieces in HBSS buffer (Invitrogen) and pressed through a 100 micron cell strainer (BD Biosciences, San Jose, CA) to obtain single cell suspensions. Cells were suspended in RPMI-1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/mL penicillin, 100 U/mL streptomycin, 50 &#x003bc;M 2-mercaptoethanol, 1 mM sodium pyruvate, and nonessential amino acids (all from Invitrogen) and incubated for 6 hrs at 37&#x000b0;C at a density of 1 &#x000d7; 10<sup>6 </sup>cells/ml with 1 &#x003bc;M ionomycin, 20 ng/ml phorbol-12-myristate acetate (EMD Biosciences, San Diego, CA) and 10 &#x003bc;g/ml brefeldin A (Sigma-Aldrich Co., St. Louis, MO). DNAse I (Sigma) was added for 5 minutes and then cells were washed once and stained with violet LIVE/DEAD Fixable Dead Cell stain (Invitrogen) for 30 minutes on ice, washed in PBS, fixed in 4% PFA, and stored at -80&#x000b0;C until analysis. Intracellular cytokine staining was performed as described previously [<xref ref-type="bibr" rid="B55">55</xref>]. Cells were stained with I-Ad FITC, DX5-PE, CD3-PE-Cy5, CD4 PerCP/Cy5.5, IFN&#x003b3; PE-Cy7, and CD8 APC-Cy7 (BD Biosciences) in PBS with 0.1% BSA, 0.1% saponin (Sigma) and 5% nonfat dry skim milk. Controls were stained with isotype matched antibodies. Samples were acquired with a 4-laser LSR II flow cytometer (BD Biosciences) and analyzed on FlowJo software (Tree Star, Inc., San Carlos, CA). Viable lymphocytes were identified by typical forward and side scatter and negative staining for LIVE/DEAD violet. T cells were identified as I-A<sup>-</sup>, CD3+ and either CD4<sup>+ </sup>or CD8<sup>+ </sup>as indicated; NK cells were identified as I-A<sup>-</sup>, CD3<sup>-</sup>, DX5+. Quadrant statistical markers were based on corresponding isotype matched controls. Samples consisted of a known fraction (typically 1/4) of the cells obtained from a whole lung, and the entire sample was analyzed (typically 2 &#x02013; 4 &#x000d7; 10<sup>5 </sup>events) yielding the absolute number of cells per lung.</p></sec><sec><title>Isolation of neutrophils from wild type and IFN&#x003b3;R-/- mice</title><p>Neutrophils were isolated from wild type and IFN&#x003b3;R-/- mice as described [<xref ref-type="bibr" rid="B56">56</xref>]. Briefly, 2 mL intraperitoneal injection of thioglycollate was administered and 4 hours later, mice were sacrificed and cells were harvested by peritoneal flush with 10 mL PBS (without calcium or magnesium). Cells were washed, red blood cells lysed with distilled water, and viability determined at &#x0003e;95% by trypan blue exclusion. Further isolation via Ficoll/Hypaque density gradient centrifugation yielded neutrophil purities of 85 &#x02013; 99% as determined by modified Giemsa staining of cytospin preparations.</p></sec><sec><title>Absolute quantification of CCR1 expression</title><p>Total RNA was isolated from neutrophils elicited from wild type and IFN&#x003b3;R -/- mice using the RT<sup>2 </sup>qPCR-Grade RNA Isolation Kit (SuperArray Bioscience Corporation). The cDNA was prepared using the 1<sup>st </sup>strand cDNA Synthesis Kit for RT-PCR (AMV; Roche Applied Science). QPCR was performed using the TaqMan Universal PCR Maser Mix (Applied BioSystems) with primer-probe pairs for GAPDH (TaqMan Rodent GAPDH Control Reagents VIC probe Applied Biosysystems) or CCR1 (chemokine (C-C motif) receptor 1 Mm00438260_s1 FAM labled, Applied Biosystems). The standard curve for mouse GAPDH included serial dilutions of the DECA template GAPDH-Mouse probe (Ambion); the standard curve for mouse CCR1 included serial dilutions of the coding sequence (GenBank Accession # <ext-link ext-link-type="gen" xlink:href="U28404">U28404</ext-link>) in pCEP4. Reactions were run in triplicate in the 7500 RealTime PCR System (Applied Biosystems); data presented as copies of CCR1 per 10<sup>9 </sup>copies GAPDH.</p></sec><sec><title>Intracellular calcium measurements</title><p>Intracellular calcium measurements were performed in a Benchtop Scanning Fluorometer and Integrated Fluid Transfer Workstation (Flexstation; Molecular Devices) as described [<xref ref-type="bibr" rid="B56">56</xref>]. Briefly, 2.5 &#x000d7; 10<sup>5 </sup>thioglycollate-elicited neutrophils were suspended in 100 &#x003bc;l of Hank's buffered saline solution with 20 mM HEPES and 100 &#x003bc;l fluorescent dye (FLIPPER calcium 3 assay kit component A; Molecular Devices) in a 96 well plate. The cells were incubated at 37&#x000b0;C for 30 minutes, centrifuged for 5 minutes, and challenged with various concentrations of CCL3, buffer alone (negative control) or f-MLF (positive control). Changes in intracellular calcium concentration were recorded as relative fluorescence units (RFU).</p></sec><sec><title>Construction vCCL3 and control (vctrl) overexpression vectors</title><p>Generation of overexpression vectors was accomplished using the commercially available AdEasy XL vector system (Stratgene, La Jolla CA) according to the manufacturer's instructions. Briefly, murine CCL3 (GenBank Accesion No. <ext-link ext-link-type="gen" xlink:href="NM 011337">NM 011337</ext-link>) was ligated into the multiple cloning site of the shuttle vector, pShuttleCMV; the corresponding control plasmid, containing the &#x003b2;-galactosidase gene, was supplied with the kit. The constructs were linearized with <italic>Pme </italic>I and transformed into an <italic>E. coli </italic>strain, (<ext-link ext-link-type="gen" xlink:href="BJ5183">BJ5183</ext-link>) which contains the replication-incompetent pAD-1 backbone. Transformants were selected for kanamycin resistance, and recombinants subsequently identified by restriction digestion. Once recombinants were identified, they were produced in bulk using the recombination-deficient bacterial strain, XL-10 Gold. Purified recombinant plasmid DNA was digested with <italic>Pac </italic>I to expose inverted terminal repeats and used to transfect AD-293 cells in which the deleted viral assembly genes are complemented <italic>in vivo</italic>. The resulting constructs, vctrl and vCCL3 were harvested from the transfected AD-293 cells when more than 90% of the monolayer exhibited cytopathic effects. Secondary stocks were produced in a similar fashion. Titration was performed by standard plaque assay. The concentration of secondary stocks reached titers of ~10<sup>12 </sup>pfu/ml for each construct. Viral stocks were stored at -80&#x000b0;C prior to use.</p></sec><sec><title>Bronchoalveolar lavage (BAL) and differential cell counts</title><p>At time points indicated, BAL fluids were harvested from 5 mice by trans-tracheal instillation and removal of pre-chilled phosphate-buffered saline with 0.25% bovine serum albumin (BSA; 0.80 ml instillation with recovery of 0.5 to 0.6 ml per mouse). Neutrophil counts were determined by visual inspection of methanol-fixed cytospin preparations stained with modified Giemsa (DiffQuik, Fisher Scientific, Pittsburgh PA).</p></sec><sec><title>Chemokine and cytokine determinations</title><p>Concentrations of CCL3 and IFN&#x003b3; were determined in BAL fluid (pg/ml) isolated as previously described [<xref ref-type="bibr" rid="B13">13</xref>] from five mice per datapoint, using commercially available ELISA kits (R&#x00026;D Systems, Minneapolis, MN). Total protein was determined the Bradford colorimetric assay using bovine serum albumin standards</p></sec><sec><title>Gross and microscopic pathology and immunohistochemical detection of CCL3</title><p>Paraffin blocks of formalin-fixed lung tissue from mice challenged with vctrl or vCCL3 were paraffin-embedded and sectioned. Standard hematoxylin and eosin staining of formalin-fixed tissue was performed by American Histolabs (Gaithersburg, MD). To detect CCL3 protein expression <italic>in situ</italic>, slides were incubated with a 1:50 dilution of goat anti-CCL3 (R&#x00026;D Systems, Minneapolis, MN) followed by a 1:400 dilution of biotinylated rabbit anti-goat Ig and developing reagents (performed by Histoserv, Inc., Germantown, MD).</p></sec><sec><title>Virus titer</title><p>Quantitative reverse transcriptase PCR to document PVM titer in mouse lung tissue was as described previously [<xref ref-type="bibr" rid="B57">57</xref>]. Datapoints are presented as copies of PVM SH gene per 10<sup>9 </sup>copies GAPDH.</p></sec><sec><title>Statistical analysis</title><p>Experimental datapoints were from triplicate samples, experiments replicated two to three times. Data were evaluated by Student's t-test or Mann-Whitney U-test as appropriate.</p></sec></sec><sec><title>Abbreviations</title><p>CCL3: CC chemokine ligand 3; IFN&#x003b3;: interferon-gamma; IFN&#x003b3;R: interferon-gamma receptor; PVM: pneumonia virus of mice; RSV: respiratory syncytial virus; CCR1: CC chemokine receptor 1; BAL: bronchoalveolar lavage; &#x003b2;gal: beta galactosidase; NK: natural killer; CCL19: CC chemokine ligand 19; PFU: plaque forming units; RFU: relative fluorescence units.</p></sec><sec><title>Authors' contributions</title><p> CB contributed to the initial design of the CCL3 overexpression studies and carried out the experimental work. CP contributed to the design of the virus infection studies and carried out the experimental work, also purified mouse neutrophils and determined CCR1 expression by quantitative RT-PCR. KD contributed to the design of the virus infection and neutrophil purification studies, reviewed the manuscript and assisted in design of the display items. JG assisted with the neutrophil purification protocol and performed the calcium transient studies. CP and BF designed and executed of the flow cytometry and intracellular cytokine staining studies. JD designed and provided direct overview of the CCL3 overexpression studies, and wrote the first draft of the manuscript. HR designed and provided direct overview of the virus infection studies, compiled the subsequent and final drafts of the manuscript and figures and oversaw the manuscript submission and revision.</p><p>All authors read and approved the final manuscript.</p></sec><sec><title>Author Information</title><p> Joseph B. Domachowske, M. D. is Professor of Pediatrics, Microbiology and Immunology at SUNY Upstate Medical University, Syracuse, New York. Helene F. Rosenberg, M. D. is Senior Investigator and Section Chief in the Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. Drs. Domachowske and Rosenberg have collaborated extensively, and together have developed the pneumonia virus of mice (PVM) model for the study of the sequelae severe respiratory virus infection in a rodent host.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>The authors thank Ms. Leslie Pesnicak for assistance with the intraperitoneal inoculations. Grant support provided by Children's Miracle Network of NY to JBD and NIAID DIR funding to HFR.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>TT</given-names></name><name><surname>Ewig</surname><given-names>S</given-names></name><name><surname>Rodloff</surname><given-names>AC</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>E</given-names></name></person-group><article-title>Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data</article-title><source>Clin Infect Dis</source><year>2006</year><volume>43</volume><fpage>748</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">16912951</pub-id><pub-id pub-id-type="doi">10.1086/506430</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>J</given-names></name><name><surname>Numa</surname><given-names>A</given-names></name><name><surname>Newth</surname><given-names>CJ</given-names></name></person-group><article-title>Acute respiratory distress syndrome caused by respiratory syncytial virus</article-title><source>Pediatr Pulmonol</source><year>1997</year><volume>23</volume><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">9094725</pub-id><pub-id pub-id-type="doi">10.1002/(SICI)1099-0496(199703)23:3&#x0003c;176::AID-PPUL2&#x0003e;3.0.CO;2-M</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>T</given-names></name><name><surname>Qiao</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>He</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name></person-group><article-title>Acute respiratory distress syndrome induced by avian influenza A (H5N1) virus in mice</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>174</volume><fpage>1011</fpage><lpage>1017</lpage><pub-id pub-id-type="pmid">16917113</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200511-1751OC</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>JH</given-names></name><name><surname>Wang</surname><given-names>LM</given-names></name><name><surname>Perng</surname><given-names>RP</given-names></name></person-group><article-title>Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome</article-title><source>J Chin Med Assoc</source><year>2005</year><volume>68</volume><fpage>4</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">15742856</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salto-Tellez</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name></person-group><article-title>ARDS in SARS: cytokine mediators and treatment implications</article-title><source>Cytokine</source><year>2005</year><volume>29</volume><fpage>92</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">15598444</pub-id><pub-id pub-id-type="doi">10.1016/j.cyto.2004.09.002</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ginsburg</surname><given-names>HS</given-names></name><name><surname>Horsfall</surname><given-names>FL</given-names><suffix>Jr</suffix></name></person-group><article-title>Characteristics of the multiplication cycle of pneumonia virus of mice (PVM)</article-title><source>J Exp Med</source><year>1951</year><volume>93</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">14803639</pub-id><pub-id pub-id-type="doi">10.1084/jem.93.2.151</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Bonville</surname><given-names>CA</given-names></name><name><surname>Easton</surname><given-names>AJ</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name></person-group><article-title>The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention</article-title><source>Pharmacol Ther</source><year>2005</year><volume>105</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15626452</pub-id><pub-id pub-id-type="doi">10.1016/j.pharmthera.2004.09.001</pub-id></citation></ref><ref id="B8"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Easton</surname><given-names>AJ</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Cane P</surname></name></person-group><article-title>Pneumonia virus of mice</article-title><source>Perspectives in Medical Virology</source><year>2006</year><volume>12</volume><fpage>299</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/S0168-7069(06)14010-0</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name></person-group><article-title>Pneumonia virus of mice: severe respiratory infection in a natural host</article-title><source>Immunol Lett</source><year>2008</year><volume>118</volume><fpage>6</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18471897</pub-id><pub-id pub-id-type="doi">10.1016/j.imlet.2008.03.013</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>NJ</given-names></name><name><surname>Ellis</surname><given-names>JA</given-names></name><name><surname>Bonville</surname><given-names>CA</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name></person-group><article-title>Immunization strategies for the prevention of pneumovirus infections</article-title><source>Expert Rev Vaccines</source><year>2007</year><volume>6</volume><fpage>169</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">17408367</pub-id><pub-id pub-id-type="doi">10.1586/14760584.6.2.169</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>LH</given-names></name><name><surname>Friedland</surname><given-names>JS</given-names></name><name><surname>Sharland</surname><given-names>M</given-names></name></person-group><article-title>Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection</article-title><source>Expert Rev Anti Infect Ther</source><year>2007</year><volume>5</volume><fpage>415</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">17547506</pub-id><pub-id pub-id-type="doi">10.1586/14787210.5.3.415</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonville</surname><given-names>CA</given-names></name><name><surname>Bennett</surname><given-names>NJ</given-names></name><name><surname>Koehnlein</surname><given-names>M</given-names></name><name><surname>Haines</surname><given-names>DM</given-names></name><name><surname>Ellis</surname><given-names>JA</given-names></name><name><surname>DelVecchio</surname><given-names>AM</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name></person-group><article-title>Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis</article-title><source>Virology</source><year>2006</year><volume>349</volume><fpage>87</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">16563455</pub-id><pub-id pub-id-type="doi">10.1016/j.virol.2006.02.017</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Domachowske</surname><given-names>JB</given-names></name><name><surname>Bonville</surname><given-names>CA</given-names></name><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name><name><surname>Easton</surname><given-names>AJ</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name></person-group><article-title>The chemokine macrophage-inflammatory protein-1alpha and its receptor CCR1 control pulmonary inflammation and antiviral host defense in paramyxovirus infection</article-title><source>J Immunol</source><year>2000</year><volume>165</volume><fpage>2677</fpage><lpage>2682</lpage><pub-id pub-id-type="pmid">10946298</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonville</surname><given-names>CA</given-names></name><name><surname>Easton</surname><given-names>AJ</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name></person-group><article-title>Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents</article-title><source>J Virol</source><year>2003</year><volume>77</volume><fpage>1237</fpage><lpage>1244</lpage><pub-id pub-id-type="pmid">12502841</pub-id><pub-id pub-id-type="doi">10.1128/JVI.77.2.1237-1244.2003</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonville</surname><given-names>CA</given-names></name><name><surname>Lau</surname><given-names>VK</given-names></name><name><surname>DeLeon</surname><given-names>JM</given-names></name><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Easton</surname><given-names>AJ</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name></person-group><article-title>Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection <italic>in vivo</italic></article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>7984</fpage><lpage>7989</lpage><pub-id pub-id-type="pmid">15254170</pub-id><pub-id pub-id-type="doi">10.1128/JVI.78.15.7984-7989.2004</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wheelock</surname><given-names>EF</given-names></name></person-group><article-title>Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin</article-title><source>Science</source><year>1965</year><volume>149</volume><fpage>310</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1126/science.149.3681.310</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pitrez</surname><given-names>PM</given-names></name><name><surname>Brennan</surname><given-names>CS</given-names></name><name><surname>Sly</surname><given-names>PD</given-names></name></person-group><article-title>Inflammatory profile in nasal secretions of infants hospitalized with acute lower airway tract infections</article-title><source>Respirology</source><year>2005</year><volume>10</volume><fpage>365</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">15955151</pub-id><pub-id pub-id-type="doi">10.1111/j.1440-1843.2005.00721.x</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Melendi</surname><given-names>GA</given-names></name><name><surname>Laham</surname><given-names>FR</given-names></name><name><surname>Monsalvo</surname><given-names>AC</given-names></name><name><surname>Casellas</surname><given-names>JM</given-names></name><name><surname>Israel&#x000ed;</surname><given-names>V</given-names></name><name><surname>Polack</surname><given-names>NR</given-names></name><name><surname>Kleeberger</surname><given-names>SR</given-names></name><name><surname>Polack</surname><given-names>FP</given-names></name></person-group><article-title>Cytokine profiles in the respiratory tract during primary infection with human metapneumovirus, respiratory syncytial virus, or influenza virus in infants</article-title><source>Pediatrics</source><year>2007</year><volume>120</volume><fpage>e410</fpage><lpage>e415</lpage><pub-id pub-id-type="pmid">17671045</pub-id><pub-id pub-id-type="doi">10.1542/peds.2006-3283</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Semple</surname><given-names>MG</given-names></name><name><surname>Dankert</surname><given-names>HM</given-names></name><name><surname>Ebrahimi</surname><given-names>B</given-names></name><name><surname>Correia</surname><given-names>JB</given-names></name><name><surname>Booth</surname><given-names>JA</given-names></name><name><surname>Stewart</surname><given-names>JP</given-names></name><name><surname>Smyth</surname><given-names>RL</given-names></name><name><surname>Hart</surname><given-names>GA</given-names></name></person-group><article-title>Severe respiratory syncytial virus bronchiolitis in infants is associated with reduced airway interferon gamma and substance P</article-title><source>PLoS ONE</source><year>2007</year><volume>2</volume><fpage>e1038</fpage><pub-id pub-id-type="pmid">17940602</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0001038</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Renzi</surname><given-names>PM</given-names></name><name><surname>Turgeon</surname><given-names>JP</given-names></name><name><surname>Marcotte</surname><given-names>JE</given-names></name><name><surname>Drblik</surname><given-names>SP</given-names></name><name><surname>Berube</surname><given-names>D</given-names></name><name><surname>Gagnon</surname><given-names>MF</given-names></name><name><surname>Spier</surname><given-names>S</given-names></name></person-group><article-title>Reduced interferon-gamma production in infants with bronchiolitis and asthma</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><fpage>1417</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">10228104</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aberle</surname><given-names>JH</given-names></name><name><surname>Aberle</surname><given-names>SW</given-names></name><name><surname>Dworzak</surname><given-names>MN</given-names></name><name><surname>Mandl</surname><given-names>SW</given-names></name><name><surname>Rebhandl</surname><given-names>W</given-names></name><name><surname>Vollnhofer</surname><given-names>G</given-names></name><name><surname>Kundi</surname><given-names>M</given-names></name><name><surname>Popow-Kraupp</surname><given-names>T</given-names></name></person-group><article-title>Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>160</volume><fpage>1263</fpage><lpage>1268</lpage><pub-id pub-id-type="pmid">10508817</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bont</surname><given-names>L</given-names></name><name><surname>Heijnen</surname><given-names>CJ</given-names></name><name><surname>Kavelaars</surname><given-names>A</given-names></name><name><surname>van Aalderen</surname><given-names>WM</given-names></name><name><surname>Brus</surname><given-names>F</given-names></name><name><surname>Draaisma</surname><given-names>JM</given-names></name><name><surname>Pekelharing-Berghuis</surname><given-names>M</given-names></name><name><surname>van Diemen-Steenvoorde</surname><given-names>RA</given-names></name><name><surname>Kimpen</surname><given-names>JL</given-names></name></person-group><article-title>Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity</article-title><source>J Infect Dis</source><year>2001</year><volume>184</volume><fpage>355</fpage><lpage>358</lpage><pub-id pub-id-type="pmid">11443563</pub-id><pub-id pub-id-type="doi">10.1086/322035</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Legg</surname><given-names>JP</given-names></name><name><surname>Hussain</surname><given-names>IR</given-names></name><name><surname>Warner</surname><given-names>JA</given-names></name><name><surname>Johnston</surname><given-names>SL</given-names></name><name><surname>Warner</surname><given-names>JO</given-names></name></person-group><article-title>Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>168</volume><fpage>633</fpage><lpage>639</lpage><pub-id pub-id-type="pmid">12773328</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200210-1148OC</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>FE</given-names></name><name><surname>Walsh</surname><given-names>EE</given-names></name><name><surname>Falsey</surname><given-names>AR</given-names></name><name><surname>Lumb</surname><given-names>ME</given-names></name><name><surname>Okam</surname><given-names>NV</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Divekar</surname><given-names>AA</given-names></name><name><surname>Hall</surname><given-names>CB</given-names></name><name><surname>Mossmann</surname><given-names>TR</given-names></name></person-group><article-title>Human infant respiratory syncytial virus (RSV) &#x02013; specific type 1 and 2 cytokine responses ex vivo during primary RSV infection</article-title><source>J Infect Dis</source><year>2007</year><volume>195</volume><fpage>1779</fpage><lpage>1788</lpage><pub-id pub-id-type="pmid">17492594</pub-id><pub-id pub-id-type="doi">10.1086/518249</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YM</given-names></name><name><surname>Miyahara</surname><given-names>N</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Prpich</surname><given-names>J</given-names></name><name><surname>Oh</surname><given-names>A</given-names></name><name><surname>Balhorn</surname><given-names>A</given-names></name><name><surname>Joetham</surname><given-names>A</given-names></name><name><surname>Gelfand</surname><given-names>EW</given-names></name><name><surname>Dakhama</surname><given-names>A</given-names></name></person-group><article-title>IFN-gamma production during initial infection determines the outcome of reinfection with respiratory syncytial virus</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>177</volume><fpage>208</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">17962634</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200612-1890OC</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mej&#x000ed;as</surname><given-names>A</given-names></name><name><surname>Ch&#x000e1;vez-Bueno</surname><given-names>S</given-names></name><name><surname>R&#x000ed;os</surname><given-names>AM</given-names></name><name><surname>Saavedra-Lozano</surname><given-names>J</given-names></name><name><surname>Fonseca Aten</surname><given-names>M</given-names></name><name><surname>Hatfield</surname><given-names>J</given-names></name><name><surname>Kapur</surname><given-names>P</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>AM</given-names></name><name><surname>Jafri</surname><given-names>HS</given-names></name><name><surname>Ramilo</surname><given-names>O</given-names></name></person-group><article-title>Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model</article-title><source>Antimicrob Agents Chemother</source><year>2004</year><volume>48</volume><fpage>1811</fpage><lpage>1822</lpage><pub-id pub-id-type="pmid">15105140</pub-id><pub-id pub-id-type="doi">10.1128/AAC.48.5.1811-1822.2004</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Durbin</surname><given-names>JE</given-names></name><name><surname>Durbin</surname><given-names>RK</given-names></name></person-group><article-title>Respiratory syncytial virus-induced immunoprotection and immunopathology</article-title><source>Viral Immunol</source><year>2004</year><volume>17</volume><fpage>370</fpage><lpage>380</lpage><pub-id pub-id-type="pmid">15357903</pub-id><pub-id pub-id-type="doi">10.1089/vim.2004.17.370</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>TR</given-names></name><name><surname>Mertz</surname><given-names>SE</given-names></name><name><surname>Gitiban</surname><given-names>N</given-names></name><name><surname>Hammond</surname><given-names>S</given-names></name><name><surname>Legallo</surname><given-names>R</given-names></name><name><surname>Durbin</surname><given-names>RK</given-names></name><name><surname>Durbin</surname><given-names>JE</given-names></name></person-group><article-title>Role for innate IFNs in determining respiratory syncytial virus immunopathology</article-title><source>J Immunol</source><year>2005</year><volume>174</volume><fpage>7234</fpage><lpage>7241</lpage><pub-id pub-id-type="pmid">15905569</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Claassen</surname><given-names>EA</given-names></name><name><surname>Kant</surname><given-names>PA van der</given-names></name><name><surname>Rychnavska</surname><given-names>ZS</given-names></name><name><surname>van Bleek</surname><given-names>GM</given-names></name><name><surname>Easton</surname><given-names>AJ</given-names></name><name><surname>Most</surname><given-names>RG van der</given-names></name></person-group><article-title>Activation and inactivation of antiviral CD8 T cell responses during murine pneumovirus infection</article-title><source>J Immunol</source><year>2005</year><volume>175</volume><fpage>6597</fpage><lpage>6604</lpage><pub-id pub-id-type="pmid">16272314</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>S</given-names></name><name><surname>Krempl</surname><given-names>CD</given-names></name><name><surname>Schmitt-Graf</surname><given-names>A</given-names></name><name><surname>Ehl</surname><given-names>S</given-names></name></person-group><article-title>The role of T cells in virus control and disease after infection with pneumonia virus of mice</article-title><source>J Virol</source><year>2008</year><volume>82</volume><fpage>11619</fpage><lpage>11627</lpage><pub-id pub-id-type="pmid">18815308</pub-id><pub-id pub-id-type="doi">10.1128/JVI.00375-08</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>DN</given-names></name><name><surname>Beck</surname><given-names>MA</given-names></name><name><surname>Coffman</surname><given-names>TM</given-names></name><name><surname>Kirby</surname><given-names>SL</given-names></name><name><surname>Sheridan</surname><given-names>JF</given-names></name><name><surname>Pragnell</surname><given-names>IB</given-names></name><name><surname>Smithies</surname><given-names>O</given-names></name></person-group><article-title>Requirement of MIP-1 alpha for an inflammatory response to viral infection</article-title><source>Science</source><year>1995</year><volume>269</volume><fpage>1583</fpage><lpage>1585</lpage><pub-id pub-id-type="pmid">7667639</pub-id><pub-id pub-id-type="doi">10.1126/science.7667639</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olszewski</surname><given-names>MA</given-names></name><name><surname>Huffnagle</surname><given-names>GB</given-names></name><name><surname>McDonald</surname><given-names>RA</given-names></name><name><surname>Lindell</surname><given-names>DM</given-names></name><name><surname>Moore</surname><given-names>BB</given-names></name><name><surname>Cook</surname><given-names>DN</given-names></name><name><surname>Toews</surname><given-names>GB</given-names></name></person-group><article-title>The role of macrophage inflammatory protein-1 alpha/CCL3 in regulation of T cell-mediated immunity to Cryptococcus neoformans infection</article-title><source>J Immunol</source><year>2000</year><volume>165</volume><fpage>6429</fpage><lpage>6436</lpage><pub-id pub-id-type="pmid">11086082</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nys</surname><given-names>M</given-names></name><name><surname>Deby-Dupont</surname><given-names>G</given-names></name><name><surname>Habraken</surname><given-names>Y</given-names></name><name><surname>Legrand-Poels</surname><given-names>S</given-names></name><name><surname>Kohnen</surname><given-names>S</given-names></name><name><surname>Ledoux</surname><given-names>D</given-names></name><name><surname>Canivet</surname><given-names>JL</given-names></name><name><surname>Damas</surname><given-names>P</given-names></name><name><surname>Lamy</surname><given-names>Y</given-names></name></person-group><article-title>Bronchoalveolar lavage fluids of ventilated patients with acute lung injury activate NF-kappaB in alveolar epithelial cell line: role of reactive oxygen/nitrogen species and cytokines</article-title><source>Nitric Oxide</source><year>2003</year><volume>9</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">14559430</pub-id><pub-id pub-id-type="doi">10.1016/j.niox.2003.07.001</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>KY</given-names></name><name><surname>Arcaroli</surname><given-names>JJ</given-names></name><name><surname>Abraham</surname><given-names>E</given-names></name></person-group><article-title>Early alterations in neutrophil activation are associated with outcome in acute lung injury</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>167</volume><fpage>1567</fpage><lpage>1574</lpage><pub-id pub-id-type="pmid">12626346</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200207-664OC</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arcaroli</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>KY</given-names></name><name><surname>Yum</surname><given-names>HK</given-names></name><name><surname>Kupfner</surname><given-names>J</given-names></name><name><surname>Pitts</surname><given-names>TM</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Strassheim</surname><given-names>D</given-names></name><name><surname>Abraham</surname><given-names>E</given-names></name></person-group><article-title>Effects of catecholamines on kinase activation in lung neutrophils after hemorrhage or endotoxemia</article-title><source>J Leukoc Biol</source><year>2002</year><volume>72</volume><fpage>571</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">12223526</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geerts</surname><given-names>L</given-names></name><name><surname>Jorens</surname><given-names>PG</given-names></name><name><surname>Willems</surname><given-names>J</given-names></name><name><surname>De Ley</surname><given-names>M</given-names></name><name><surname>Slegers</surname><given-names>H</given-names></name></person-group><article-title>Natural inhibitors of neutrophil function in acute respiratory distress syndrome</article-title><source>Crit Care Med</source><year>2001</year><volume>29</volume><fpage>1920</fpage><lpage>1924</lpage><pub-id pub-id-type="pmid">11588452</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200110000-00012</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Moore</surname><given-names>EE</given-names></name><name><surname>Tamura</surname><given-names>DY</given-names></name><name><surname>Zallen</surname><given-names>G</given-names></name><name><surname>Biffl</surname><given-names>WL</given-names></name><name><surname>Silliman</surname><given-names>CC</given-names></name></person-group><article-title>Interleukin-6 augments neutrophil cytotoxic potential via selective enhancement of elastase release</article-title><source>J Surg Res</source><year>1998</year><volume>76</volume><fpage>91</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">9695746</pub-id><pub-id pub-id-type="doi">10.1006/jsre.1998.5295</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M</given-names></name><name><surname>Horuk</surname><given-names>R</given-names></name><name><surname>Bhatia</surname><given-names>M</given-names></name></person-group><article-title>Treatment with BX471, a nonpeptide CCR1 antagonist, protects mice against acute pancreatitis-associated lung injury by modifying neutrophil recruitment</article-title><source>Pancreas</source><year>2007</year><volume>34</volume><fpage>233</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">17312463</pub-id><pub-id pub-id-type="doi">10.1097/mpa.0b013e31802e7598</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anh</surname><given-names>DB</given-names></name><name><surname>Faisca</surname><given-names>P</given-names></name><name><surname>Desmecht</surname><given-names>DJ</given-names></name></person-group><article-title>Differential resistance/susceptibility patterns to pneumovirus infection among inbred mouse strains</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2006</year><volume>291</volume><fpage>L426</fpage><lpage>L435</lpage><pub-id pub-id-type="pmid">16556725</pub-id><pub-id pub-id-type="doi">10.1152/ajplung.00483.2005</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>PS</given-names></name><name><surname>Flanagan</surname><given-names>BF</given-names></name><name><surname>Hart</surname><given-names>CA</given-names></name><name><surname>Smyth</surname><given-names>RL</given-names></name></person-group><article-title>Production of chemokines in the lungs of infants with severe respiratory syncytial virus bronchiolitis</article-title><source>J Infect Dis</source><year>2005</year><volume>191</volume><fpage>1225</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">15776367</pub-id><pub-id pub-id-type="doi">10.1086/428855</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>AM</given-names></name><name><surname>Bonville</surname><given-names>CA</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name></person-group><article-title>Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><fpage>1918</fpage><lpage>1924</lpage><pub-id pub-id-type="pmid">10351940</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>KJ</given-names></name><name><surname>Su</surname><given-names>IJ</given-names></name><name><surname>Theron</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>YC</given-names></name><name><surname>Lai</surname><given-names>SK</given-names></name><name><surname>Liu</surname><given-names>CC</given-names></name><name><surname>Lei</surname><given-names>HY</given-names></name></person-group><article-title>An interferon-gamma related cytokine storm in SARS patients</article-title><source>J Med Virol</source><year>2005</year><volume>75</volume><fpage>185</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">15602737</pub-id><pub-id pub-id-type="doi">10.1002/jmv.20255</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>WG</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Murphy</surname><given-names>B</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><article-title>Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice</article-title><source>J Immunol</source><year>2004</year><volume>173</volume><fpage>4030</fpage><lpage>4039</lpage><pub-id pub-id-type="pmid">15356152</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>YT</given-names></name><name><surname>Liao</surname><given-names>F</given-names></name><name><surname>Hsiao</surname><given-names>CH</given-names></name><name><surname>Kao</surname><given-names>CL</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Wu-Hsieh</surname><given-names>BA</given-names></name></person-group><article-title>Modeling the early events of severe acute respiratory syndrome coronavirus infection <italic>in vitro</italic></article-title><source>J Virol</source><year>2006</year><volume>80</volume><fpage>2684</fpage><lpage>2693</lpage><pub-id pub-id-type="pmid">16501078</pub-id><pub-id pub-id-type="doi">10.1128/JVI.80.6.2684-2693.2006</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Chan</surname><given-names>PKS</given-names></name><name><surname>Chan</surname><given-names>KF</given-names></name><name><surname>Lee</surname><given-names>WK</given-names></name><name><surname>Lam</surname><given-names>WY</given-names></name><name><surname>Wong</surname><given-names>KF</given-names></name><name><surname>Tang</surname><given-names>NLS</given-names></name><name><surname>Tsang</surname><given-names>DNC</given-names></name><name><surname>Sung</surname><given-names>RYT</given-names></name><name><surname>Buckley</surname><given-names>TA</given-names></name><name><surname>Tam</surname><given-names>JS</given-names></name><name><surname>Cheng</surname><given-names>AF</given-names></name></person-group><article-title>Pathology of fatal human infection associated with avian influenza A H5N1 virus</article-title><source>J Med Virol</source><year>2001</year><volume>63</volume><fpage>242</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">11170064</pub-id><pub-id pub-id-type="doi">10.1002/1096-9071(200103)63:3&#x0003c;242::AID-JMV1007&#x0003e;3.0.CO;2-N</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szretter</surname><given-names>KJ</given-names></name><name><surname>Gangappa</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Wun-Ju</surname><given-names>S</given-names></name><name><surname>Zaki</surname><given-names>SR</given-names></name><name><surname>Sambhara</surname><given-names>S</given-names></name><name><surname>Tumpey</surname><given-names>TM</given-names></name><name><surname>Katz</surname><given-names>JM</given-names></name></person-group><article-title>Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice</article-title><source>J Virol</source><year>2007</year><volume>81</volume><fpage>2736</fpage><lpage>2744</lpage><pub-id pub-id-type="pmid">17182684</pub-id><pub-id pub-id-type="doi">10.1128/JVI.02336-06</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Law</surname><given-names>HKW</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Ng</surname><given-names>IHY</given-names></name><name><surname>Peiris</surname><given-names>JSM</given-names></name><name><surname>Lau</surname><given-names>YL</given-names></name></person-group><article-title>Differential expression of chemokines and their receptors in adult and neonatal macrophages infected with human or avian influenza viruses</article-title><source>J Infect Dis</source><year>2006</year><volume>194</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">16741883</pub-id><pub-id pub-id-type="doi">10.1086/504690</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Wynn</surname><given-names>TA</given-names></name><name><surname>Chang</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Broxmeyer</surname><given-names>HE</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Tiffany</surname><given-names>HL</given-names></name><name><surname>Westphal</surname><given-names>H</given-names></name><name><surname>Kwon-Chung</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name></person-group><article-title>Impaired host defense, hematopoiesis, granulomatous inflammation and type 1-type 2 cytokine balance in mice lacking CC chemokine receptor 1</article-title><source>J Exp Med</source><year>1997</year><volume>185</volume><fpage>1959</fpage><lpage>1968</lpage><pub-id pub-id-type="pmid">9166425</pub-id><pub-id pub-id-type="doi">10.1084/jem.185.11.1959</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>TN</given-names></name><name><surname>Beaman</surname><given-names>BL</given-names></name></person-group><article-title>Interferon-&#x003b3; activation of polymorphonuclear neutrophil function</article-title><source>Immunology</source><year>2004</year><volume>112</volume><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">15096178</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2567.2004.01849.x</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>BD</given-names></name><name><surname>Finbloom</surname><given-names>DS</given-names></name></person-group><article-title>Characterization of the interaction between recombinant human interferon-&#x003b3; and its receptor on human polymorphonuclear leukocytes</article-title><source>J Leukoc Biol</source><year>1990</year><volume>47</volume><fpage>64</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">2136748</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bonecchi</surname><given-names>R</given-names></name><name><surname>Polentarutti</surname><given-names>N</given-names></name><name><surname>Luini</surname><given-names>W</given-names></name><name><surname>Borsatti</surname><given-names>A</given-names></name><name><surname>Bernasconi</surname><given-names>S</given-names></name><name><surname>Locati</surname><given-names>M</given-names></name><name><surname>Power</surname><given-names>C</given-names></name><name><surname>Proudfoot</surname><given-names>A</given-names></name><name><surname>Wells</surname><given-names>TN</given-names></name><name><surname>Mackay</surname><given-names>C</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name><name><surname>Sozzani</surname><given-names>S</given-names></name></person-group><article-title>Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-g in human neutrophils</article-title><source>J Immunol</source><year>1999</year><volume>162</volume><fpage>474</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">9886422</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khader</surname><given-names>SA</given-names></name><name><surname>Partida-Sanchez</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>G</given-names></name><name><surname>Jelley-Gibbs</surname><given-names>DM</given-names></name><name><surname>Swain</surname><given-names>S</given-names></name><name><surname>Pearl</surname><given-names>JE</given-names></name><name><surname>Ghilardi</surname><given-names>N</given-names></name><name><surname>Desauvage</surname><given-names>FJ</given-names></name><name><surname>Lund</surname><given-names>FE</given-names></name><name><surname>Cooper</surname><given-names>AM</given-names></name></person-group><article-title>Interleukin 12p40 is required for dendritic cell migration and T cell priming after <italic>Mycobacterium tuberculosis </italic>infection</article-title><source>J Exp Med</source><year>2006</year><volume>203</volume><fpage>1805</fpage><lpage>1815</lpage><pub-id pub-id-type="pmid">16818672</pub-id><pub-id pub-id-type="doi">10.1084/jem.20052545</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalton</surname><given-names>DK</given-names></name><name><surname>Pitts-Meek</surname><given-names>S</given-names></name><name><surname>Keshav</surname><given-names>S</given-names></name><name><surname>Figari</surname><given-names>IS</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name><name><surname>Stewart</surname><given-names>TA</given-names></name></person-group><article-title>Multiple defects of immune cell function in mice with disrupted interferon-gamma genes</article-title><source>Science</source><year>1993</year><volume>259</volume><fpage>1739</fpage><lpage>1742</lpage><pub-id pub-id-type="pmid">8456300</pub-id><pub-id pub-id-type="doi">10.1126/science.8456300</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Hendriks</surname><given-names>W</given-names></name><name><surname>Althage</surname><given-names>A</given-names></name><name><surname>Hemmi</surname><given-names>S</given-names></name><name><surname>Bluethmann</surname><given-names>H</given-names></name><name><surname>Kamijo</surname><given-names>R</given-names></name><name><surname>Vilcek</surname><given-names>J</given-names></name><name><surname>Zinkernagel</surname><given-names>RM</given-names></name><name><surname>Aguet</surname><given-names>M</given-names></name></person-group><article-title>Immune response in mice that lack the interferon-gamma receptor</article-title><source>Science</source><year>1993</year><volume>259</volume><fpage>1742</fpage><lpage>1745</lpage><pub-id pub-id-type="pmid">8456301</pub-id><pub-id pub-id-type="doi">10.1126/science.8456301</pub-id></citation></ref><ref id="B55"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>B</given-names></name><name><surname>Prussin</surname><given-names>C</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Coligan JE, Kruisbeek AM, Marguilies DH, Shevach EM, Strober W</surname></name></person-group><article-title>Unit 6.24, Detection of intracellular cytokines by flow cytometry</article-title><source>Current Protocols in Immunology</source><year>2003</year><publisher-name>Wiley</publisher-name><fpage>6.24.1</fpage><lpage>6.24.16</lpage><pub-id pub-id-type="pmid">18432901</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>JL</given-names></name><name><surname>Guillabert</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Le</surname><given-names>Y</given-names></name><name><surname>Urizar</surname><given-names>E</given-names></name><name><surname>Seligman</surname><given-names>E</given-names></name><name><surname>Fang</surname><given-names>KJ</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Imbault</surname><given-names>V</given-names></name><name><surname>Communi</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name><name><surname>Parmentier</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>PM</given-names></name><name><surname>Migeotte</surname><given-names>I</given-names></name></person-group><article-title>F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor</article-title><source>J Immunol</source><year>2007</year><volume>178</volume><fpage>1450</fpage><lpage>1456</lpage><pub-id pub-id-type="pmid">17237393</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ellis</surname><given-names>JA</given-names></name><name><surname>Martin</surname><given-names>BV</given-names></name><name><surname>Waldner</surname><given-names>C</given-names></name><name><surname>Dyer</surname><given-names>KD</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name></person-group><article-title>Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>1085</fpage><lpage>1095</lpage><pub-id pub-id-type="pmid">17052820</pub-id><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.09.081</pub-id></citation></ref></ref-list></back></article> 